Benefits due to immunization against measles.
作者信息
Axnick N W, Shavell S M, Witte J J
出版信息
Public Health Rep (1896). 1969 Aug;84(8):673-80.
Abstract
摘要
相似文献
1
Benefits due to immunization against measles.
Public Health Rep (1896). 1969 Aug;84(8):673-80.
2
Evaluating the benefits of increasing measles immunization rates.
Health Serv Res. 2001 Oct;36(5):885-909.
3
Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
Arch Pediatr Adolesc Med. 2005 Dec;159(12):1136-44. doi: 10.1001/archpedi.159.12.1136.
4
The benefits from 10 years of measles immunization in the United States.
Public Health Rep. 1975 May-Jun;90(3):205-7.
5
Pharmacists in the continuing fight against measles.
Hosp Pharm. 1991 Feb;26(2):133-5, 140, 142.
6
Measles control in developing and developed countries: the case for a two-dose policy.
Bull World Health Organ. 1993;71(1):93-103.
7
Comprehensive health planning and its relation to cost.
J La State Med Soc. 1970 May;122(5):128-32.
8
Progress toward implementation of a second-dose measles immunization requirement for all schoolchildren in the United States.
J Infect Dis. 2004 May 1;189 Suppl 1:S98-103. doi: 10.1086/374720.
9
Expanded programme on immunization. International importations of measles from the Americas into the United States, 1990-1994.
Wkly Epidemiol Rec. 1995 Jun 9;70(23):164-6.
10
Presidential address: The cost of health.
Surgery. 1976 Sep;80(3):283-8.
引用本文的文献
1
Measles and rubella: From global health challenges to advancements in molecular diagnostics in the elimination era.
Mol Ther Nucleic Acids. 2025 Sep 2;36(4):102698. doi: 10.1016/j.omtn.2025.102698. eCollection 2025 Dec 9.
2
From jurisdiction to veridiction: Expertise and economization of immunization policy in the United States.
Econ Soc. 2025 Jun 26;54(2):310-333. doi: 10.1080/03085147.2025.2517951. eCollection 2025.
3
Recent developments in decision-analytic modelling for economic evaluation.
Pharmacoeconomics. 2006;24(11):1043-53. doi: 10.2165/00019053-200624110-00002.
4
Setting prices for new vaccines (in advance).
Int J Health Care Finance Econ. 2003 Sep;3(3):207-24. doi: 10.1023/a:1025336903645.
5
The average cost of measles cases and adverse events following vaccination in industrialised countries.
BMC Public Health. 2002 Sep 19;2:22. doi: 10.1186/1471-2458-2-22.
6
Pharmacoeconomics of immunisation: a review.
Pharmacoeconomics. 1993 Apr;3(4):286-308. doi: 10.2165/00019053-199303040-00005.
7
Measles control in developing and developed countries: the case for a two-dose policy.
Bull World Health Organ. 1993;71(1):93-103.
8
A selected public health bibliography with annotations.
Am J Public Health Nations Health. 1970 Jan;60(1):214-8. doi: 10.2105/ajph.60.1.214.
9
Benefits, risks and costs of immunization for measles, mumps and rubella.
Am J Public Health. 1985 Jul;75(7):739-44. doi: 10.2105/ajph.75.7.739.
10
Costs and benefits of a second measles inoculation of children in Israel, the West Bank, and Gaza.
J Epidemiol Community Health. 1990 Dec;44(4):274-80. doi: 10.1136/jech.44.4.274.
本文引用的文献
1
Medical importance of measles.
Am J Dis Child. 1962 Mar;103:224-6. doi: 10.1001/archpedi.1962.02080020236005.
2
Propagation in tissue cultures of cytopathogenic agents from patients with measles.
Proc Soc Exp Biol Med. 1954 Jun;86(2):277-86. doi: 10.3181/00379727-86-21073.
3
Economic cost of St. Louis encephalitis epidemic in Dallas, Texas, 1966.
Public Health Rep (1896). 1968 Oct;83(10):860-6.
4
Progress of measles eradication in the United States.
Public Health Rep (1896). 1968 Mar;83(3):245-8.
5
Epidemiologic basis for eradication of measles in 1967.
Public Health Rep (1896). 1967 Mar;82(3):253-6.
Zotero 插件